Trial · NCT01590771
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Sitagliptin | -0.88 | 95% Confidence Interval -0.99 to -0.76 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Placebo | -0.27 | 95% Confidence Interval -0.38 to -0.15 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Sitagliptin | -40.7 | 95% Confidence Interval -49.4 to -31.9 | mg/dL | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Placebo | -7.7 | 95% Confidence Interval -16.6 to 1.2 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Sitagliptin | -24.4 | 95% Confidence Interval -29.1 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin | Placebo | -7.7 | 95% Confidence Interval -12.3 to -3.0 | mg/dL | |
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin | Sitagliptin | -0.86 | 95% Confidence Interval -1.01 to -0.71 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin | Placebo | -0.45 | 95% Confidence Interval -0.60 to -0.30 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Sitagliptin | -0.85 | 95% Confidence Interval -1.04 to -0.67 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Placebo | -0.05 | 95% Confidence Interval -0.24 to 0.14 | Percent of glycosylated hemoglobin (A1C) | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin | Sitagliptin | -33.4 | 95% Confidence Interval -43.4 to -23.5 | mg/dL | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin | Placebo | -6.2 | 95% Confidence Interval -16.1 to 3.7 | mg/dL | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Sitagliptin | -49.5 | 95% Confidence Interval -62.9 to -36.2 | mg/dL | |
| Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Placebo | -11.9 | 95% Confidence Interval -25.8 to 2.0 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin | Sitagliptin | -22.2 | 95% Confidence Interval -28.4 to -16.0 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin | Placebo | -5.7 | 95% Confidence Interval -11.9 to 0.5 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Sitagliptin | -26.3 | 95% Confidence Interval -33.3 to -19.4 | mg/dL | |
| Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone | Placebo | -9.3 | 95% Confidence Interval -16.3 to -2.3 | mg/dL | |
| Number of Participants Who Experienced an Adverse Event | Sitagliptin | 106 | Participants | ||
| Number of Participants Who Experienced an Adverse Event | Placebo | 98 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01590771/results